← Back to Home

Nine tumors reported after Zolgensma treatment, with signs of vector DNA integration found in two cases

A new safety signal has emerged for this gene therapy for spinal muscular atrophy. Evidence of vector DNA integration was detected in two cases, but not all nine reports can be attributed to treatment; a UK expert team currently recommends no additional testing or changes to routine follow-up.

By SURL BioNews

Safety follow-up must continue for years after gene therapy delivers the required gene into cells. Novartis recently confirmed that, since Zolgensma was first approved in 2019, it has received nine reports of tumors in patients who had received the treatment. Evidence that vector DNA had integrated into the patients’ DNA was found in two cases. This raises a warning about a possible link between the treatment and tumors, but the nine cases cannot all be considered drug-caused.

Zolgensma treats spinal muscular atrophy (SMA) by using an adeno-associated virus type 9 (AAV9) vector to deliver a functional SMN1 gene into motor neurons. The current safety concern centers on the vector used to deliver the gene: Novartis said the potential risk of tumors arising from vector integration is already included in the drug’s prescribing information. Evidence of integration in two cases now provides clinical clues that require further clarification.

Different sources describe the two cases with differing degrees of certainty. In an update published by SMA UK on November 4, the UK Zolgensma National Multidisciplinary Team said that tumor pathology examinations had been completed in three of the nine cases. Two were described as treatment-related, while the other appeared unrelated. Novartis used more cautious language in its November 5 statement, confirming evidence of vector DNA integration in two cases and saying that both patients had received treatment and remained under follow-up. How the evidence of integration relates to tumor formation still requires clarification through complete case data and regulatory assessment.

The reports also raise questions about how safety information is communicated to families. STAT reported that seven of the nine cases had not previously been made public. Novartis disclosed the information to neurologists earlier that week, after which it reached the public through channels including patient advocacy groups. BioSpace separately obtained direct confirmation of the nine reports from Novartis and noted that a causal relationship with the therapy had not been established for the remaining seven cases. A relationship that has not been established has not necessarily been ruled out.

Novartis said that more than 6,000 patients worldwide have received Zolgensma through clinical trials, managed access programs and commercial treatment. However, dividing the nine reports by the number of treated patients cannot directly yield a tumor incidence rate or a measure of the drug’s cancer risk: publicly available information is currently insufficient to establish the full follow-up periods, case backgrounds and reporting circumstances, or to determine whether the risk is higher than originally expected.

For families whose children have received treatment, the UK National Multidisciplinary Team, based on the available information, has recommended no changes to routine care or follow-up and no additional imaging, other testing or monitoring. These are the team’s care recommendations based on current evidence; they do not mean the case investigations have concluded.

According to information from patient organizations cited by STAT and BioSpace, regulators are reviewing the relevant evidence. Novartis also said it had notified health authorities of each case and would continue to cooperate. The next questions to clarify are the tumors’ pathological characteristics, the relationship between vector integration and tumor formation, and the test results for the remaining cases. These data will determine whether this safety signal needs to lead to new risk information or follow-up measures.

References

  1. SWI swissinfo.ch / Keystone-SDA
  2. Spinal Muscular Atrophy UK / National Multidisciplinary Team for Zolgensma
  3. STAT
  4. BioSpace